Abstract
Neovascular glaucoma (NVG) is an aggressive type of glaucoma, which often results in poor visual outcomes. Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia. Bevacizumab is a humanized anti-VEGF monoclonal IgG1 antibody. The potential of antivascular endothelial growth factor (anti-VEGF) agents to modify the disease course of neovascular glaucoma (NVG) was recognized shortly after their use in the treatment of age-related macular degeneration was reported. These medications were noted to induce rapid regression of the anterior segment neovascularization that characterizes NVG. Several studies as well as extensive clinical experience have demonstrated a rapid regression of anterior segment neovascularization following the injection of anti-VEGF agents. This review aims to summarize current evidences regarding effectiveness of Bevacizumab in management of neovascular glaucoma.
Highlights
Neovascular glaucoma (NVG) is an aggressive type of glaucoma that often causes poor visual results
Antivascular endothelial growth factor is frequently used for various conditions in which VEGF release is induced in response to retinal ischemia
This review aims to summarize the current evidence regarding the efficacy of bevacizumab in the treatment of neovascular glaucoma
Summary
Neovascular glaucoma (NVG) is an aggressive type of glaucoma that often causes poor visual results. A prospective, interventional case series included 50 patients (51 eyes) with NVG divided into central retinal vein occlusion (CRVO) and proliferative diabetic retinopathy (PDR) followed up for 6–30 months reported that; 39 eyes displayed controlled IOP (≤21 mmHg) after treatment.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
